In addition, increasing evidences suggest that overexpression of EZH2 in cancers contribute to a more aggressive clinical behavior [16], [25], which is likely mediated in part through silencing the expression of cell cycle inhibitors p15INK4B and p16INK4A[37], [38]. This evidence concerns the gene CDKN2A and cancer.